su011248

Renal Cell Carcinoma

Peking University Cancer Hospital & InstitutePhase 4 / ApprovedActive

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 71/ 100
Competitive Position: 65/ 100

Competitive context

144 Active assets in the Renal Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Everolimus Merck Sharp & Dohme LLC	Phase 4	BB
Alpha-Interferon Fuzhou General Hospital	Phase 3	BB
Nivolumab Fred Hutchinson Cancer Center	Phase 4	BB
Axitinib SWOG Cancer Research Network	Phase 4	BB
Pembrolizumab City of Hope Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Carcinoma, Small Cell LungDormant

BB

Indicative ·

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.